December 1, 2016 - By Ruchi Gupta · 0 Comments
Bio Rad Laboratories Inc (NYSE:BIO) institutional sentiment increased to 1.08 in 2016 Q2. Its up 0.01, from 1.07 in 2016Q1. The ratio has improved, as 97 active investment managers increased and opened new equity positions, while 91 cut down and sold their holdings in Bio Rad Laboratories Inc. The active investment managers in our partner’s database now own: 17.57 million shares, down from 18.21 million shares in 2016Q1. Also, the number of active investment managers holding Bio Rad Laboratories Inc in their top 10 equity positions was flat from 1 to 1 for the same number . Sold All: 20 Reduced: 71 Increased: 79 New Position: 18.
Bio-Rad Laboratories, Inc. is a maker and distributor of life science research and clinical diagnostics products. The company has a market cap of $5.10 billion. The Firm makes and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It has a 52.52 P/E ratio. Bio-Rad operates in two divisions: Life Science and Clinical Diagnostics.
About 110,855 shares traded hands. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 21.36% since April 28, 2016 and is uptrending. It has outperformed by 15.44% the S&P500.
Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on February, 23. They expect $0.93 EPS, down 44.64% or $0.75 from last year’s $1.68 per share. BIO’s profit will be $27.19M for 46.90 P/E if the $0.93 EPS becomes a reality. After $0.62 actual EPS reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts 50.00% EPS growth.
According to Zacks Investment Research, “Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company’s products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California.”
Tikvah Management Llc holds 11.55% of its portfolio in Bio-Rad Laboratories, Inc. for 138,007 shares. Sector Gamma As owns 129,124 shares or 3.74% of their US portfolio. Moreover, Intrepid Capital Management Inc has 2.75% invested in the company for 48,583 shares. The New York-based Levin Capital Strategies L.P. has invested 2.05% in the stock. Ariel Investments Llc, a Illinois-based fund reported 980,851 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 insider purchases, and 19 selling transactions for $2.57 million net activity.
Ratings analysis reveals 100% of Bio-Rad Laboratories’s analysts are positive. Out of 2 Wall Street analysts rating Bio-Rad Laboratories, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $143 while the high is $225. The stock’s average target of $187 is 7.19% above today’s ($174.45) share price. BIO was included in 5 notes of analysts from August 7, 2015. CL King initiated Bio-Rad Laboratories, Inc. (NYSE:BIO) on Thursday, October 13 with “Buy” rating. Jefferies maintained the shares of BIO in a report on Wednesday, September 7 with “Buy” rating.
Bio-Rad Laboratories, Inc. (Bio-Rad), incorporated on March 10, 1975, is a maker and distributor of life science research and clinical diagnostics products. The Firm makes and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two divisions: Life Science and Clinical Diagnostics. The Company’s Life Science segment develops, makes, sells and services reagents, apparatus and instruments used for biological research. The Company’s Clinical Diagnostics segment develops, makes, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. Bio-Rad sells over 8,000 services and products to a client base consisting of scientific research, healthcare, education and government clients around the world.
More news for Bio-Rad Laboratories, Inc. (NYSE:BIO) were recently published by: Law360.com, which released: “Bio-Rad Says Ex-GC Faked FCPA Concerns To Save Job” on November 24, 2016. Businesswire.com‘s article titled: “Microbiome MDx specialist Genetic Analysis and Bio-Rad Sign Agreement” and published on November 28, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta